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Expression of Signaling Mediators Downstream of
EGF-Receptor Predict Sensitivity to Small Molecule
Inhibitors Directed Against the EGF-Receptor Pathway
Martin L. Sos, MD,*† Thomas Zander, MD,* Roman K. Thomas, MD,*†
Andrea Staratschek-Jox, MD,* Julia Claasen,* and Ju¨rgen Wolf, MD*
The EGF-receptor (EGFR) and downstream signaling molecules
have emerged as promising targets for inhibition by small molecules
in the treatment of nonsmall cell lung cancer (NSCLC). In this study
expression of pivotal signaling molecules in the EGFR pathway
were used to predict response to inhibitors of the EGFR signaling
cascade. NSCLC cell lines were treated with the EGFR tyrosine
kinase inhibitor (TKI) gefitinib and PD16,8393, the AKT inhibitor
SH-6 and LY294002, the farnesyltransferase inhibitor L744832, and
the mTOR inhibitor rapamycin. Response was correlated to expres-
sion of AKT, p-AKT, EGFR, S6K1, p-S6K1, PTEN and to the
mutation status of EGFR and KRAS. As expected, mutation of the
EGFR predicted response to EGFR-TKI. The resistance mutation
T790M conferred resistance to treatment with gefitinib, but not to
the irreversible EGFR inhibitor PD16,8393. In cell lines indepen-
dent of the EGFR, expression of PTEN correlated with resistance to
AKT inhibition, EGFR expression correlated to resistance to 17-
AAG and L744832 and S6K1 as well as p-S6K1 expression corre-
lated with sensitivity to rapamycin.
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In the new era of targeted therapy in nonsmall cell lungcancer (NSCLC), paved by the tremendous success of
EGF-receptor (EGFR) tyrosine kinase inhibitor (TKI), new
inhibitors and reliable predictive markers for response rates
are crucial. In the case of EGFR-TKI, mutations in the EGFR
highly correlate to sensitivity to those small molecules.1
However, all patients initially responding to EGFR-TKIs will
suffer from relapse of the disease, in some cases (50%)
because of the occurrence of a second-site mutation in the
EGFR KD.2,3 Inhibitors targeting downstream molecules of
EGFR might improve the outcome.
The EGFR mediates activating signals via a cascade of
kinases such as RAS/RAF and Pi3K/AKT/mTOR. Members
of this pathway can be either mutated (KRAS) or dysregu-
lated on different cellular levels (PTEN, AKT) and thus be
oncogenic in NSCLC.4,5 Activation of EGFR leads to phos-
phorylation of AKT while PTEN negatively regulates this
prosurvival signal. mTOR is critical for cellular proliferation
and is both, activated and an activator itself of AKT.6 A panel
of small molecules can address those crucial molecules in an
indirect, as in the case of 17-AAG (Hsp90 inhibition) and in
a direct manner, as in the case of SH-6 (AKT inhibition) or
rapamycin (mTOR inhibition).
Here we aimed at analyzing the dependence of NSCLC
cells on signaling through the Pi3K/AKT/mTOR pathway.
Furthermore, we sought for molecular predictors of sensitiv-
ity to inhibitors of this pathway.
MATERIALS AND METHODS
Cell Lines and Chemicals
Cell lines were obtained from the German Collection of
Microorganisms and Cell Cultures (DSMZ; HCC15, HCC44,
HCC78, HCC366, A549) and the American Type Culture
Collection (ATCC; H358, H1666, H1975, H3255). All cell
lines except for A549 were maintained in RPMI 1640 sup-
plemented with 10 to 20% FCS, L-glutamine 1%, and peni-
cillin–streptomycin 1%. PD16,8393, SH-6, LY294002, and
rapamycin were obtained from Alexis (Gru¨nberg, Germany),
L744832 from Calbiochem (San Diego). Gefitinib was pro-
vided by AstraZeneca (Edinburgh, UK). EGF was purchased
by R&D Systems (Minneapolis).
Viability Assays
Viability of cultured cells at optimized cell density
(0.5–2  104 cells/well) was assessed by XTT assay (Roche
Diagnostics, Germany) after incubation for 72 hours, accord-
ing to the instructions of the manufacturer. Viability was
expressed as difference of the vehicle control after back-
ground subtraction and IC50 (concentration needed to inhibit
the viability of 50% of the cells) was calculated by fitting
sigmoidal curves to the obtained data.
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Western Blotting
Cells (3–4  106) were harvested and washed twice
with ice-cold PBS and lysed in Triton X-100 buffer contain-
ing 1 mM PMSF (1:500) and protease-inhibitors (Roche
Diagnostics).7 The following antibodies were used: poly-
clonal, full-length PTEN; polyclonal, c-terminal EGFR
(Santa Cruz, Germany); polyclonal, c-terminal AKT; poly-
clonal p-AKT, polyclonal, raised against residues 185 to 205
S6K1; polyclonal p-S6K1 (Cell Signaling, USA), polyclonal
p-EGFR (Cell Signaling), -actin antibodies (Chemicon,
USA); antirabbit-antibody, antimouse (Dako, Germany). The
enhanced chemiluminescence system (Amersham-Pharma-
cia) was used to develop the blots. Quantitative analysis of
the results was achieved by measurement of the intensity of
each blot with ImageJ software.
PCR and Sequencing
Following oligonucleotides were used for PCR:
GAPDH_FWD 5-TGATGACATCAAGAAGGTGGTGAA-3;
GAPDH_REV 5-TCCTTGGAGGCCATGTGGGCCAT-3;
EGFR Ex18-FWD 5-GCATGGTGAGGGCTGAGGTGA-
3; EGFR Ex18-REV 5-CCCCACCAGACCATGAGAGGC-3;
EGFR Ex19-FWD 5-CAGATCACTGGGCAGCATGTGG-3;
EGFR Ex19-REV 5-TTTAGGATGTGGAGATGAGCAGG-
3; EGFR Ex20-FWD 5-ATCGCATTCATGCGTCTTCA-3;
EGFR Ex20-Rev 5-ATCCCCATGGCAAACTCTTG-3; EGFR
Ex21-FWD 5-CCATGATGATCTGTCCCTCACA-3; EGFR
Ex21-REV 5-AATACAGCTAGTGGGAAGGCAG-3; K-
RAS Ex2-FWD 5-GAATGGTCCTGCACCAGTAA-3; K-RAS
Ex2-REV 5-GTGTGACATGTTCTAATATAGTCA-3;
K-RAS Ex2-FWDint 5-GTCCTGCACCAGTAATATGC-
3; K-RAS Ex2-REVint 5-ATGTTCTAATATAGTCA-
CATTTTC-3. Sanger sequencing was performed and an-
alyzed on a 96 capillary sequencer. RefSeq Database was
taken for reference sequences; EGFR (NM NM1956),
KRAS (NM NM3845).
Statistical Methods
In the EGFR independent cell lines correlation between
relative viability (%) assessed by XTT after treatment with
each compound at each given concentration and each quan-
titative value of the protein intensity as measured by Western
blotting for each protein, was determined by using Pearson
product-moment correlation coefficient (r2) and its respective
p value using R-project as a software tool. Hierarchical
clustering of correlation coefficients (r2) was performed using
dCHIP.
RESULTS
Correlation of Mutations in the EGFR and
KRAS With Sensitivity to Small Molecules
Targeting the EGFR Pathway
Based on the different IC50 values determined by XTT
assays, we defined 2 groups of cell lines: sensitive (IC50  1
M), and resistant (IC50  1 M). This classification reca-
pitulates clinical responders where typical concentrations of
0.01 M are found to be potent.8 According to this scheme,
7 cell lines were resistant to gefitinib (A549, H358, HCC78,
HCC15, HCC44, HCC366, and H1975). H3255 was the cell
line with the highest sensitivity to gefitinib (IC50  0.001
M) and also H1666 showed sensitivity in nanomolar range
(IC50  0.832 M). All cell lines sensitive to gefitinib were
also sensitive to PD16,8393. One cell line resistant to ge-
fitinib (H1975), harboring the T790M mutation, demon-
strated sensitivity to PD16,8393 (Figure 1A). H1975 may
therefore be called dependent of the EGFR although resistant
to gefitinib. As expected, sequencing of the EGFR revealed a
heterozygous L858R mutation in H1975 and H3255. Se-
quencing of exon 20 revealed the T790M mutation in 1975
cells as previously described.3,9
KRAS gene mutations are known to occur mutually
exclusive to EGFR mutations and to be associated with
FIGURE 1. Different sensitivity of lung cancer
cell lines to treatment with gefitinib. A, Exem-
plary viability data for H3255, H1975, and
HCC44 where the relative viability (x axis) is dis-
played against the nanomolar concentration of a
given compound (y axis). Similar results were
obtained for the further 6 cell lines analyzed. B,
Chemical structures of the reversible EGFR-TKI
gefitinib and the 2 irreversible EGFR-TKI
PD16,8393 and EKB-5569. C, Description of cell
lines on histologic, mutational, and phenotypical
level. Results of sequence analysis of EGFR exon
18–21 and KRAS. Scc, squamous cell carcinoma;
bac, bronchioalveolar adenocarcinoma; ad, ade-
nocarcinoma; n.d., not determined; D, To de-
scribe the sensitivity of a given cell line to an in-
hibitor, IC50-values (concentration needed to
inhibit the viability of 50% of the cells) were cal-
culated by fitting sigmoidal curves to the ob-
tained data. The results for all screened cell lines
and all inhibitors are displayed.
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resistance to EGFR-TKI.10 DNA sequence analysis of KRAS
revealed mutations in codon 12 in the A549 (G12S), HCC44
(G12C), and H358 (G12C) cell lines (Figure 1C). Thus, the
differential sensitivity of our panel of NSCLC cell lines is
partly reflected by the mutational patterns in the genes EGFR
and KRAS conferring sensitivity or resistance to EGFR-TKI.
To understand the impact of the KRAS mutation on the
sensitivity to a farnesyl transferase inhibitor we analyzed all cell
lines for sensitivity to L744832. For all KRAS-mutated cells
(A549, HCC44, and H358) only concentrations above 20 M
resulted in a significant inhibition of cellular growth (IC50 
70.8, 55.0, and 20.8 M). The IC50s observed for cell lines
without KRAS mutations tended to be higher (Figure 1D).
Correlation of Protein Expression and
Sensitivity in EGFR Independent Cell Lines
To predict sensitivity to inhibitors targeting the EGFR
pathway in EGFR-TKI resistant cell lines [all cell lines that
show resistance (IC50  1 M) to either gefitinib or
PD168393] we determined steady-state protein expression
levels of EGFR, PTEN, AKT, p-AKT, S6K1, and pS6K1 by
immunoblotting (Figure 2A) and correlated these expression
levels to the viability data [relative viability (%) assessed by
XTT for each measured concentration] after treatment with
gefitinib, PD16,8393, 17-AAG, SH-6, LY294002, rapamy-
cin, and L744832. Next correlation coefficients (1 r2) were
used for hierarchical clustering (Figure 2B). As expected,
correlation was similar for different concentrations of the
respective compound. Those cell lines with the highest ex-
pression of EGFR demonstrated a relative sensitivity to
PD16,8393 (r2 for PD16,8393 0.1 M  0.82; P  0.044).
By contrast, high expression of EGFR correlated with resis-
tance to 17-AAG and L744832 (r2 for 17-AAG 0.01 M 
0.89, P  0.015 and r2 for L744832 20 M  0.82, P 
0.044). In this group of EGFR-independent cell lines, we
detected high levels of PTEN expression to predict resistance
to SH-6 (SH-6 4 M r2  0.79, P  0.058). S6K1 and
p-S6K1 predicted relative sensitivity to rapamycin and 17-
AAG (r2 for 17-AAG 1 M  0.8 (S6K), P  0.054 and r2
for rapamycin 0.08 nM  0.77 (S6K), P  0.067).
DISCUSSION
Inhibition of the EGFR has turned out to be the first
promising therapeutic option in advanced NSCLC since de-
cades. However, the high rate of nonresponders and the low
survival benefit suggest that this therapeutic approach might
still be improved. To address this problem, we performed an
analysis of established NSCLC cell lines in search for bio-
logic markers predictive for sensitivity to EGFR, RAS, AKT,
and mTOR inhibition.
Given the systematic approach of our analysis these
observations may be of relevance for the improvement of
EGFR pathway targeted therapy in NSCLC although we
cannot exclude off-targets effects of the inhibitors that may
contribute to our results.
FIGURE 2. Prediction of sensitivity of EGFR-
TKI resistant cell lines to inhibition with differ-
ent small molecules. A, Baseline expression of
EGFR, PTEN, p-AKT, AKT, p-S6K, and S6K in all
EGFR-TKI resistant cell lines. Actin expression
was used as loading control. B, Hierarchical
clustering of correlation coefficients (r2) of
steady-state protein expression and sensitivity
to a given inhibitor was performed for all
EGFR-TKI resistant cell lines.
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Mutations within the kinase domain of the EGFR were
the first markers to consistently predict response to EGFR-
TKI.8 To date most mutated NSCLC cells are sensitive to
EGFR-TKI and second mutations may be gained respectively
clonally selected by EGFR-TKI treatment.2,3 One EGFR-
mutated NSCLC cell line resistant to gefitinib (H1975) har-
bors the T790M mutation responsible for the secondary
resistance to gefitinib.11 PD16,8393 forming a covalent bond
to a Cys residue (Cys 773) in the catalytic domain of the
EGFR was cytotoxic to H1975, underlining the different
mechanism of inhibition of this compound.12 Similar results
were obtained by other irreversible EGFR inhibitors structur-
ally related to PD16,8393 such as EKB-569 (Figure 1B).13 To
our knowledge this is the first description of PD16,8393 as an
effective compound in cell lines with the secondary resistance
mutation T790M.
One of the target genes of the EGFR signaling pathway
is the small GTPase RAS whose family member KRAS is
found to be mutated in 15 to 30% of lung adenocarcinoma.5
The exclusive character of KRAS mutations regarding its
co-occurance with EGFR mutations described in recent pub-
lications9 is affirmed in our limited cell line based approach.
Farnesyltransferase inhibitors such as L744832 obviate pre-
nylation of the RAS oncoprotein and hence its activation. In
our panel of cell lines we did not observe any clear associa-
tion between KRAS-mutations and the sensitivity to farnesyl-
transferase inhibitor.
Hsp90 inhibitors like 17-AAG interact specifically with
a single molecular target causing instability and degradation
of client proteins such as EGFR, Her2, and AKT.14 As seen
in other studies 17-AAG is active in most cell lines in
low-nanomolar doses.14 Interestingly, in our panel of cell
lines expression of EGFR correlates significantly and nega-
tively with the sensitivity to 17-AAG. The observation that
depletion of EGFR in EGFR-overexpressing cell lines is
much slower if compared with Her2 might partly explain
our results.14
AKT activation is frequent in lung cancer and transfec-
tion of wildtype AKT increases invasiveness of NSCLC
cells.4 SH-6, a newly designed AKT inhibitor,15 is a phos-
phatidylinositol ether lipid analogue (PIA) and thus a revers-
ible AKT inhibitor, active in PTEN wildtype and PTEN
mutated cells.15 Our results reveal PTEN as a negative pre-
dictive marker for the sensitivity to SH-6 inhibition in EGFR-
TKI resistant cells.
mTOR is one of the main targets of phospho-AKT. We
used rapamycin as an experimental compound for mTOR
targeting and measured S6K1 expression as the protein is
directly activated by mTOR.6 S6K1 expression and phos-
phorylation status were predictive for sensitivity to mTOR
inhibition by rapamycin, as seen in a recent study that was
carried out in breast cancer cell lines.16
In summary, we have provided a simple and reliable
tool for prediction of sensitivity to small molecule inhibitors
based on a model cohort of NSCLC cell lines. Our approach
highlights the importance of systematic perturbation experi-
ments in vitro as the crucial step toward individual targeted
therapy in vivo.
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